View Older Stories View More Recent Stories

Apr 2, 2019 07:00AM Sangamo and Pfizer Announce Phase 1/2 Interim Data For Investigational Hemophilia A Gene Therapy
Mar 28, 2019 03:00AM The EIU's Index of Cancer Preparedness reveals huge gaps in health system readiness and governance
Mar 20, 2019 12:00PM Merck KGaA and Pfizer (PFE) Announce Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Untreated Advanced Ovarian Cancer
Mar 20, 2019 11:58AM Merck KGaA, Darmstadt, Germany, and Pfizer Announce Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Untreated Advanced Ovarian Cancer
Mar 20, 2019 06:46AM Pfizer (PFE) Buys 15% Stake and Option to Acquire Gene Therapy Company Vivet Therapeutics
Mar 20, 2019 06:45AM Pfizer Secures Exclusive Option to Acquire Gene Therapy Company Vivet Therapeutics
Mar 20, 2019 06:09AM Pfizer (PFE), Merck KGaA Report Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Untreated Advanced Ovarian Cancer
Mar 19, 2019 07:15PM Merck KGaA, Darmstadt, Germany, and Pfizer Announce Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Untreated Advanced Ovarian Cancer
Mar 17, 2019 11:45AM AUGUSTUS Demonstrates Favorable Safety Results of Eliquis® Versus Vitamin K Antagonists in Non-Valvular Atrial Fibrillation Patients with Acute Coronary Syndrome and/or Undergoing Percutaneous Corona
Mar 12, 2019 06:20AM Pfizer (PFE) Reports FDA Approval of Oncology Biosimilar TRAZIMERA (trastuzumab-qyyp)
Mar 11, 2019 07:37PM U.S. FDA Approves Pfizer’s Oncology Biosimilar TRAZIMERA™ (trastuzumab-qyyp), a Biosimilar to Herceptin®1
Mar 5, 2019 10:05AM AnTolRx Announces Pfizer Exercises Option To License Immune Tolerance Therapy For Potential Treatment Of Type 1 Diabetes
Mar 5, 2019 05:52AM Pfizer (PFE) Prices $5B Debt Offering Consisting of Five Tranches of Notes
Mar 4, 2019 08:57PM Pfizer Prices $5,000,000,000 Debt Offering
Mar 1, 2019 08:36AM Pfizer (PFE) Receives Positive CHMP Opinion for LORVIQUA for Certain Adult Patients with Previously-Treated ALK-Positive Advanced NSCLC
Mar 1, 2019 08:35AM Pfizer Receives Positive CHMP Opinion for LORVIQUA® (lorlatinib) for Certain Adult Patients with Previously-Treated ALK-Positive Advanced Non-Small Cell Lung Cancer
Feb 28, 2019 08:07AM Pfizer (PFE) Announces Serotypes Included in 20VPnC Being Investigated for Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older
Feb 28, 2019 08:00AM Pfizer Announces Serotypes Included in 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older
Feb 19, 2019 10:30AM Ochsner Health System and Pfizer Partner to Develop Innovative Models for Clinical Trials
Feb 19, 2019 09:33AM Pfizer (PFE) Receives European Approval for ZIRABEV, Biosimilar to Avastin
Feb 19, 2019 09:32AM Pfizer Receives European Approval for ZIRABEV™ (bevacizumab), a Biosimilar to Avastin®*
Feb 19, 2019 06:51AM Pfizer (PFE) and Lilly (LLY) Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain
Feb 19, 2019 06:45AM Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain
Feb 19, 2019 05:54AM Merck (MRK) Reports Pivotal Phase III Data for BAVENCIO (avelumab) Plus INLYTA (axitinib) in Advanced RCC Published in New England Journal of Medicine (Earlier)
Feb 16, 2019 05:14PM Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine
Feb 11, 2019 05:45PM EMD Seron, Pfizer (PFE) Announce FDA Accepted sBLA and Granted Priority Review for BAVENCIO Plus INLYTA for Treatment of Advanced RCC
Feb 11, 2019 05:44PM FDA Accepts sBLA and Grants Priority Review for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) for the Treatment of Advanced Renal Cell Carcinoma
Feb 11, 2019 05:05PM Bristol-Myers Squibb (BMY) Announces Opdivo Plus Low-Dose Yervoy Demonstrates Continued Survival Benefit at 30-Month Follow-up in Patients with Previously Untreated Advanced or Metastatic RCC
Feb 1, 2019 09:21AM Pfizer (PFE) Reports Positive CHMP Opinion for Vizimpro (dacomitinib) Positive CHMP Opinion for Vizimpro (dacomitinib) for 1st-Line Treatment of Adult Patients
Feb 1, 2019 09:17AM Pfizer Receives Positive CHMP Opinion for Vizimpro® (dacomitinib) for the First-line Treatment of Adult Patients with Locally Advanced Or Metastatic Non-Small Cell Lung Cancer with EGFR-Activating Mu
Jan 29, 2019 06:34AM Pfizer (PFE), Lilly (LLY) Announce Top-Line Results From Second Phase 3 Study of Tanezumab in Osteoarthritis Pain
Jan 29, 2019 06:30AM Pfizer and Lilly Announce Top-Line Results From Second Phase 3 Study of Tanezumab in Osteoarthritis Pain
Jan 14, 2019 08:05AM Pfizer (PFE) Reports FDA Accepts Regulatory Submissions for Review of Tafamidis to Treat Transthyretin Amyloid Cardiomyopathy
Jan 14, 2019 08:00AM US FDA Accepts Regulatory Submissions for Review of Tafamidis to Treat Transthyretin Amyloid Cardiomyopathy
Jan 7, 2019 08:06AM Pfizer (PFE) Enters Collaboration Agreement with CytoReason
Jan 7, 2019 08:00AM CytoReason Signs Collaboration Agreement with Pfizer Inc. To Utilize CytoReason’s Machine Learning Model of the Immune System for Drug Discovery
Jan 3, 2019 08:40AM Pfizer (PFE) Begins Phase 2b/3 Clinical Trial for PF-06651600 for Treatment of Patients with Moderate to Severe Alopecia Areata
Jan 3, 2019 08:30AM Pfizer Initiates Phase 2b/3 Clinical Trial for PF-06651600, an Oral JAK3 Inhibitor, for the Treatment of Patients with Moderate to Severe Alopecia Areata
Dec 21, 2018 02:06PM UPDATE: Merck KGaA, Pfizer (PFE) to Terminate JAVELIN Ovarian 100 Trial of Avelumab
Dec 21, 2018 02:00PM Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on JAVELIN Ovarian 100 Trial of Avelumab in Previously Untreated Advanced Ovarian Cancer
Dec 20, 2018 04:31PM Pfizer (PFE) Phase 2b STRIVE Clinical Trial of Staphylococcus aureus Vaccine Discontinued Due to Futility
Dec 20, 2018 04:30PM Independent Data Monitoring Committee Recommends Discontinuation of the Phase 2b STRIVE Clinical Trial of Staphylococcus aureus Vaccine Following Planned Interim Analysis
Dec 20, 2018 11:45AM Transgene Completes Safety and Tolerability Assessment of TG4001 in Combination with Avelumab in Phase 1b Part of Trial in HPV-Positive Cancer Patients
Dec 17, 2018 08:08AM Pfizer (PFE) Enters Strategic Research Collaboration & License Agreement with Kineta Immuno-Oncology to Develop New Cancer Immunotherapies
Dec 17, 2018 08:00AM Kineta Enters Research Collaboration and License Agreement with Pfizer to Develop New Cancer Immunotherapies
Dec 14, 2018 12:10PM Pfizer Declares First-Quarter 2019 Dividend
Dec 14, 2018 10:29AM Pfizer (PFE) Receives Positive CHMP Opinion for Oncology Biosimilar, ZIRABEV
Dec 14, 2018 10:29AM Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, ZIRABEV™ (bevacizumab)
Dec 14, 2018 08:01AM Pfizer (PFE) Commences Phase 3 Program for 20-Valent Pneumococcal Conjugate Vaccine (20vPnC) Candidate, PF-06482077
Dec 14, 2018 08:00AM Pfizer Initiates Phase 3 Program for 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older
View More Recent Stories View Older Stories